Mocuis and Supect® in Orlando for ASH 2015


Orlando, FL – December 8, 2015

The 2015 American Society of Hematology (ASH) annual meeting commenced in sunny Orlando, FL from December 5-8.  ASH brings the world’s leading hematology specialists in one location.  With over 20,000 people from every sub-specialty, ASH 2015 was a success. Mocuis (모크스) was in Orlando for the heralded event joining the hematology community in sharing their meaningful information and conclusions.


ⓒ종합 경제정보 미디어 이데일리

Attendees of ASH took part in IL-Yang Pharm’s presentation of Supect’s® (Radotinib HCl) compelling Phase III efficacy and safety results for newly diagnosed CML-CP patients. Supect is a second generation tyrosine kinase inhibitor (TKI) approved in South Korea as a first line treatment for newly diagnosed chronic myeloid leukemia chronic phase (CML-CP) and for the treatment of patients with Philadelphia positive chronic myeloid leukemia (Ph+ CML) without optimal response and/or tolerance to other Bcr-Abl tyrosine kinase inhibitors.